Medexus Pharmaceuticals Statistics
Total Valuation
MEDXF has a market cap or net worth of 69.75 million. The enterprise value is 82.21 million.
| Market Cap | 69.75M |
| Enterprise Value | 82.21M |
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 32.31M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +21.73% |
| Shares Change (QoQ) | +8.97% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 29.84M |
Valuation Ratios
The trailing PE ratio is 86.54.
| PE Ratio | 86.54 |
| Forward PE | n/a |
| PS Ratio | 0.66 |
| PB Ratio | 1.32 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.58 |
| P/OCF Ratio | 3.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.98, with an EV/FCF ratio of 4.22.
| EV / Earnings | 101.99 |
| EV / Sales | 0.78 |
| EV / EBITDA | 4.98 |
| EV / EBIT | 9.82 |
| EV / FCF | 4.22 |
Financial Position
The company has a current ratio of 0.81, with a Debt / Equity ratio of 0.41.
| Current Ratio | 0.81 |
| Quick Ratio | 0.28 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 1.32 |
| Debt / FCF | 1.12 |
| Interest Coverage | 1.12 |
Financial Efficiency
Return on equity (ROE) is 1.88% and return on invested capital (ROIC) is 6.84%.
| Return on Equity (ROE) | 1.88% |
| Return on Assets (ROA) | 3.50% |
| Return on Invested Capital (ROIC) | 6.84% |
| Return on Capital Employed (ROCE) | 11.27% |
| Revenue Per Employee | 1.16M |
| Profits Per Employee | 8,857 |
| Employee Count | 91 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | -651,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.50% in the last 52 weeks. The beta is 2.03, so MEDXF's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | +8.50% |
| 50-Day Moving Average | 2.10 |
| 200-Day Moving Average | 2.11 |
| Relative Strength Index (RSI) | 50.36 |
| Average Volume (20 Days) | 8,869 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MEDXF had revenue of 105.66 million and earned 806,000 in profits. Earnings per share was 0.03.
| Revenue | 105.66M |
| Gross Profit | 63.45M |
| Operating Income | 8.44M |
| Pretax Income | 155,000 |
| Net Income | 806,000 |
| EBITDA | 16.48M |
| EBIT | 8.44M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 9.33 million in cash and 21.90 million in debt, giving a net cash position of -12.56 million.
| Cash & Cash Equivalents | 9.33M |
| Total Debt | 21.90M |
| Net Cash | -12.56M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 52.96M |
| Book Value Per Share | 1.64 |
| Working Capital | -14.67M |
Cash Flow
In the last 12 months, operating cash flow was 19.76 million and capital expenditures -276,000, giving a free cash flow of 19.48 million.
| Operating Cash Flow | 19.76M |
| Capital Expenditures | -276,000 |
| Free Cash Flow | 19.48M |
| FCF Per Share | n/a |
Margins
Gross margin is 60.05%, with operating and profit margins of 7.99% and 0.76%.
| Gross Margin | 60.05% |
| Operating Margin | 7.99% |
| Pretax Margin | 0.15% |
| Profit Margin | 0.76% |
| EBITDA Margin | 15.59% |
| EBIT Margin | 7.99% |
| FCF Margin | 18.44% |
Dividends & Yields
MEDXF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.73% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.16% |
| FCF Yield | 27.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 19, 2018. It was a reverse split with a ratio of 0.0666666.
| Last Split Date | Dec 19, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.0666666 |
Scores
MEDXF has an Altman Z-Score of 0.52 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.52 |
| Piotroski F-Score | 6 |